Financial insights for intelligent investors
We Research.
You Profit.
Prime Funds
Prime Portfolios
Prime Deposits
Prime Term Insurance
Prime Review
Our unbiased, research-backed recommendations help you invest right and stay right.
You profit better from deep research
Popular products don’t pay off. Consistent ones do. You would have made 20% lower return if you simply chose popular products. PrimeInvestor will ensure you invest in the best.
You can go ‘direct’ confidently and save costs
You can save as much as 2% by going for direct plans. You don’t need to worry about going wrong because we’re here to tell you what to do and what not to.
You won’t be a victim of bad advice
Tired of getting bad products pushed on you? No such risks with us – we’re independent, we take no commissions, and we are here only to serve you.
You will never miss a good product again
Your advisors or RMs won't tell you about great, but lesser known products. With us, you will be aware of everything that’s worth your money.
Get on the driver's seat and take control. Let PrimeInvestor be the GPS for your financial journey!
Prime Blog Articles
Cut out the market noise. Stay on top of what's relevant to you.
IPO Review: Glenmark Life Sciences – Should you invest?
Glenmark Life Sciences (GLS) is a generic API (Active Pharmaceutical Ingredients) manufacturer and a subsidiary of Glenmark Pharmaceuticals. The Glenmark Life Sciences IPO is worth Rs. 1,514 crore, comprising fresh issue of Rs.1,060 crore and an offer for sale worth Rs.454 crore by Glenmark Pharmaceuticals. Should you invest in the IPO of this high-value, non-commoditized API player?
How to evaluate banking and finance stocks
There are certain characteristics which make evaluating banking and finance stocks different from others which produce goods and services. Money cannot be lent to someone unless there is an inflow by way of capital or debt. Since it is not practical to lend only from capital, borrowing (or leverage) is the sustaining food for this business. Naturally in using this leverage, there are good and bad apples.
Why you don’t need a Rs 1 crore health policy
Recent reports suggest that as many as 35% of health insurance buyers in recent times – mainly in their 30s and 40s – are buying Rs 1 crore health insurance plans, against just 5% who used to buy them earlier.
What our customers say about us...
